Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FATENASDAQ:MREONASDAQ:RGNXNASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFATEFate Therapeutics$0.69+1.8%$1.13$0.67▼$7.35$79.07M2.262.29 million shs18,405 shsMREOMereo BioPharma Group$2.12-10.8%$2.66$2.11▼$5.02$367.70M0.711.01 million shs1.19 million shsRGNXREGENXBIO$6.53-2.2%$7.34$5.62▼$20.77$325.01M1.26767,807 shs1,360 shsSTOKStoke Therapeutics$6.11-3.1%$9.04$5.53▼$17.58$329.88M1.09715,520 shs3,368 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFATEFate Therapeutics-11.69%-22.87%-28.42%-62.22%-90.30%MREOMereo BioPharma Group-6.75%-8.30%-11.24%-40.75%-35.19%RGNXREGENXBIO-5.39%-15.68%+12.67%-14.16%-67.06%STOKStoke Therapeutics-4.55%-15.44%-16.89%-45.17%-50.84%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFATEFate Therapeutics3.4915 of 5 stars3.11.00.04.71.32.50.6MREOMereo BioPharma Group2.563 of 5 stars3.64.00.00.02.71.70.0RGNXREGENXBIO4.4587 of 5 stars4.42.00.04.61.22.51.3STOKStoke Therapeutics3.3243 of 5 stars3.60.00.04.82.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFATEFate Therapeutics 2.22Hold$5.43684.48% UpsideMREOMereo BioPharma Group 3.25Buy$7.71264.74% UpsideRGNXREGENXBIO 2.86Moderate Buy$32.78402.34% UpsideSTOKStoke Therapeutics 3.13Buy$24.67304.04% UpsideCurrent Analyst Ratings BreakdownLatest FATE, STOK, RGNX, and MREO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025MREOMereo BioPharma GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.003/26/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/20/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.003/19/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00 ➝ $47.003/19/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.003/18/2025RGNXREGENXBIOLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.003/18/2025MREOMereo BioPharma GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.003/18/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/17/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $34.003/14/2025RGNXREGENXBIOMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.003/14/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFATEFate Therapeutics$13.63M5.82N/AN/A$3.74 per share0.19MREOMereo BioPharma Group$1M328.13N/AN/A$0.36 per share5.88RGNXREGENXBIO$83.33M3.92N/AN/A$7.09 per share0.92STOKStoke Therapeutics$36.56M9.03N/AN/A$3.57 per share1.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFATEFate Therapeutics-$160.93M-$1.64N/AN/AN/A-1,325.43%-45.88%-33.95%5/8/2025 (Estimated)MREOMereo BioPharma Group-$29.47M-$0.06N/AN/AN/AN/AN/AN/A5/23/2025 (Estimated)RGNXREGENXBIO-$263.49M-$4.61N/AN/AN/A-283.19%-70.65%-41.68%5/6/2025 (Estimated)STOKStoke Therapeutics-$104.70M-$1.68N/AN/AN/A-629.90%-54.45%-40.77%5/5/2025 (Estimated)Latest FATE, STOK, RGNX, and MREO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/A3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 million3/13/2025Q4 2024RGNXREGENXBIO-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 million3/5/2025Q4 2024FATEFate Therapeutics-$0.44-$0.31+$0.13-$0.44$1.57 million$1.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFATEFate TherapeuticsN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFATEFate TherapeuticsN/A8.298.29MREOMereo BioPharma GroupN/A6.106.10RGNXREGENXBION/A3.053.05STOKStoke TherapeuticsN/A5.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFATEFate Therapeutics97.54%MREOMereo BioPharma Group62.83%RGNXREGENXBIO88.08%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipFATEFate Therapeutics5.00%MREOMereo BioPharma Group4.13%RGNXREGENXBIO13.13%STOKStoke Therapeutics11.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableMREOMereo BioPharma Group40155.15 million148.74 millionOptionableRGNXREGENXBIO37050.09 million43.04 millionOptionableSTOKStoke Therapeutics10054.08 million46.98 millionOptionableFATE, STOK, RGNX, and MREO HeadlinesRecent News About These CompaniesStoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1 at 5:06 PM | businesswire.comStoke Therapeutics remains significantly undervalued, says CanaccordApril 1 at 12:58 AM | markets.businessinsider.comResearch Analysts Set Expectations for STOK FY2025 EarningsMarch 29, 2025 | americanbankingnews.comWhat is Chardan Capital's Forecast for STOK FY2025 Earnings?March 28, 2025 | marketbeat.comFY2025 EPS Estimates for STOK Raised by Cantor FitzgeraldMarch 25, 2025 | americanbankingnews.comBrokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $23.00March 25, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Forecast for STOK EarningsMarch 24, 2025 | marketbeat.comEarnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 22, 2025 | finance.yahoo.comWhat is HC Wainwright's Forecast for STOK Q3 Earnings?March 22, 2025 | marketbeat.comLeerink Partnrs Weighs in on STOK Q1 EarningsMarch 22, 2025 | marketbeat.comQ1 EPS Estimate for Stoke Therapeutics Lifted by AnalystMarch 22, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by BrokeragesMarch 22, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,266 Shares of StockMarch 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells 3,884 Shares of StockMarch 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,382 Shares of StockMarch 21, 2025 | marketbeat.comEquities Analysts Offer Predictions for STOK Q1 EarningsMarch 21, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,266 SharesMarch 21, 2025 | insidertrades.comStoke Therapeutics' (STOK) Buy Rating Reiterated at HC WainwrightMarch 20, 2025 | marketbeat.comStoke Therapeutics' (STOK) "Buy" Rating Reiterated at Chardan CapitalMarch 20, 2025 | marketbeat.comThe Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and moreMarch 19, 2025 | mmm-online.comNeedham & Company LLC Reaffirms "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK)March 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyTaiwan Semi's $100 Billion Investment: Fate of the ChipmakersBy Gabriel Osorio-Mazilli | March 6, 2025View Taiwan Semi's $100 Billion Investment: Fate of the ChipmakersRecession Risk: Is It Going to Happen? Here Are the Key CluesBy Jea Yu | March 26, 2025View Recession Risk: Is It Going to Happen? Here Are the Key CluesUp 32% in 2025, Is Chinese E-Commerce Giant PDD Still a Buy?By Leo Miller | March 27, 2025View Up 32% in 2025, Is Chinese E-Commerce Giant PDD Still a Buy?FATE, STOK, RGNX, and MREO Company DescriptionsFate Therapeutics NASDAQ:FATE$0.69 +0.01 (+1.76%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Mereo BioPharma Group NASDAQ:MREO$2.12 -0.26 (-10.76%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.REGENXBIO NASDAQ:RGNX$6.52 -0.15 (-2.17%) As of 09:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Stoke Therapeutics NASDAQ:STOK$6.10 -0.20 (-3.10%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
